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Objectives The aim of this study was to assess the outcomes of patients at prohibitive surgical risk undergoing MitraClip
therapy (Abbott Vascular, Redwood City, California) for severe mitral regurgitation (MR).
Background The safety of percutaneous mitral valve repair has been documented. However, midterm development of mitral
valve function, ventricular remodeling, and clinical outcomes in patients not amenable to surgery are unknown.
Methods A total of 104 consecutive patients (mean age 74  9 years; 64 men; 49 and 54 with MR 3 and 4, respec-
tively; 69 with functional MR; 59 and 45 in New York Heart Association classes III and IV, respectively) were fol-
lowed for a median of 359 days.
Results Device success was achieved in 96 patients (92%). In patients with successful index procedures, MR grade
2 was present at follow-up in 82.5%, left ventricular end-diastolic and -systolic volumes were reduced,
and forward stroke volumes were significantly increased. Improvements in New York Heart Association
functional class were observed in 80% of patients, with 69% in class I or II; 75% improved in the 6-min
walk test; and 74% reported improvements in quality of life. One-year estimates of mortality and rehospital-
ization were 22% and 31%, respectively. Forward stroke volume at discharge emerged as a predictor of
event-free survival.
Conclusions MitraClip therapy improves clinical and echocardiographic outcomes at 1 year in about three-quarters of criti-
cally ill, elderly patients with moderate to severe MR not amenable to surgery. (J Am Coll Cardiol 2011;58:
2190–5) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.047The MitraClip device (Abbott Vascular, Redwood City,
California) is a novel percutaneous system to treat mitral
regurgitation (MR). In the recent EVEREST II (Endovas-
cular Valve Edge-to-Edge Repair Study), MitraClip ther-
apy was compared with mitral valve (MV) surgery for
moderate to severe MR (1) and despite lower efficacy
revealed similar improvements in clinical outcomes.
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accepted July 26, 2011.Whereas EVEREST II reported outcomes in selected
patients amenable to surgery, in this study, we assessed the
outcomes of patients not amenable for surgery undergoing
MitraClip implantation.
Methods
Patients. Between September 2008 and March 2010, 104
consecutive patients with moderate to severe MR were deter-
mined to be at prohibitive surgical risk by joint evaluation of a
panel of cardiovascular surgeons and cardiologists and thus
underwent percutaneous mitral repair. All procedures were
performed by 2 experienced operators (O.F., S.B.). Patient
characteristics are given in Table 1. The patients’ clinical status
was significantly different in several aspects from that of
EVEREST II patients (Table 2). All patients included in the
study provided written informed consent.
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November 15, 2011:2190–5 MitraClip in Patients Not Amenable to SurgeryFollow-up. Device success was pre-specified as a residual
MR grade of 2 or less after clip implantation. At 6 and 12
months, patients were subjected to a structured interview
including the Minnesota Living with Heart Failure Ques-
tionnaire (MLHFQ), transthoracic echocardiography, a
Baseline Patient Characteristics (N  104)Table 1 Baseline Patient Characteristics (N  104)
Age (yrs) 74 9
Men 64 (62%)
Logistic EuroSCORE (%) 36 (21–54)
Hypertension 80 (78%)
Hypercholesterolemia 64 (62%)
Diabetes 34 (33%)
Chronic obstructive pulmonary disease 43 (41%)
Renal failure 57 (55%)
Chronic heart failure 83 (80%)
Atrial fibrillation 66 (64%)
Coronary artery disease 68 (65%)
Myocardial infarction within previous 3 months 7 (7%)
Prior coronary artery bypass grafting 41 (39%)
Cardiomyopathy
Ischemic 47 (45%)
Dilated 34 (33%)
Valvular 2 (2%)
None 21 (20%)
MR etiology
Functional 69 (66%)
Degenerative 28 (27%)
Mixed 7 (7%)
MR severity
2 (mild to moderate) 1 (1%)
3 (moderate to severe) 49 (47%)
4 (severe) 54 (52%)
NYHA functional class
III 59 (57%)
IV 45 (43%)
Cardiovascular medication
ACE inhibitors or ARBs 83 (80%)
Aldosterone antagonists 51 (49%)
Beta-blockers 85 (83%)
Loop diuretic agents 92 (89%)
Electrical therapy
CRT 10 (10)
MLHFQ score 45 17 [n 75]
LV ejection fraction (%) 43 16
LV end-diastolic diameter (mm) 65 12
LV end-systolic diameter (mm) 53 14
LV end-diastolic volume (ml) 212 (159–279)
LV end-systolic volume (ml) 123 (74–192)
Regurgitant volume (ml) 42 (28–56)
Regurgitant fraction (%) 48 (40–59)
Effective regurgitant orifice area (mm2) 35 (23–61)
Mitral valve orifice area (cm2) 4.1 1.0
Mean transmitral pressure gradient (mm Hg) 2.0 (1.0–3.0)
Values are mean  SD, n (%), or median (interquartile range).
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; CRT  cardiac
esynchronization therapy; EuroSCORE  European System for Cardiac Operative Risk Evaluation;
V  left ventricular; MLHFQ  Minnesota Living With Heart Failure Questionnaire; MR  mitral
egurgitation; NYHA  New York Heart Association.6-min walk test, and assessment of serum N-terminal pro-brain natriuretic peptide (NT-
proBNP) levels. If a return visit
was hindered by comorbidities, re-
evaluation was restricted to tele-
phone follow-up.
Echocardiography. MR at base-
line was graded according to
American Society of Echocardiog-
raphy guidelines (2). After the in-
tervention, MR severity was as-
sessed with the technique reported
by Foster et al. (3). A description
of echocardiographic methods is
available in the Online Appendix.
Statistical analysis. A summary
of statistical methods is given in the Online Appendix.
Results
Acute outcomes. Initial device success was achieved in 96
patients (92%), with MR grade 2 present in 60 patients
and MR grade 1 in 36. In the remaining 8 patients, clip
implantation was not achieved (n  3) or did not reduce
MR to less than grade 3 (n  5). A single clip was
mplanted in 62 patients, 2 clips were implanted in 34, and
2 clips were implanted in 5. The median length of
ospital stay was 9 days (interquartile range: 7 to 14 days).
eriprocedural complications. Chordal rupture was en-
ountered in 3 patients and clip detachment in 2 patients.
f the former patients, 2 underwent prompt surgical MV
Abbreviations
and Acronyms
LV  left ventricular
MLHFQ  Minnesota Living
With Heart Failure
Questionnaire
MR  mitral regurgitation
MV  mitral valve
NT-proBNP  N-terminal
pro–brain natriuretic
peptide
NYHA  New York Heart
Association
Continuous and Prevalence of Categorical PatientVariables Sig ificantly Different From theEVEREST II Study
Table 2
Continuous and Prevalence of C t gorical Patient
Variables Significantly Different From the
EVEREST II Study
Variable
EVEREST II
(n  184)
This Study
(n  104) p Value
Age (yrs) 67 13 74 9 0.0001
Age 75 yrs 55 (30%) 64 (62%) 0.0001
NYHA functional class III or IV 94 (51%) 104 (100%) 0.0001
LV ejection fraction (%) 60 10 43 16 0.0001
Coronary artery disease 86/183 (47%) 68 (65%) 0.0031
Prior coronary artery bypass grafting 40/183 (22%) 41 (39%) 0.0018
Atrial fibrillation 59/175 (34%) 66 (64%) 0.0001
Renal failure 6 (3) 57 (55%) 0.0001
Diabetes 14 (8) 34 (33%) 0.0001
Chronic obstructive pulmonary
disease
27/183 (15%) 43 (41%) 0.0001
Functional MR 49 (27%) 69 (66%) 0.0001
EVEREST II exclusion criteria met 83 (80%)
LV ejection fraction 25% 14 (13%)
LV end-systolic diameter 55 mm 40 (38%)
Mitral valve orifice area 4 cm2 45 (43%)
Coaptation depth 11 mm 26 (25%)
Coaptation length 2 mm 18 (17%)Values are mean  SD, n (%), or n/N (%).
EVEREST II  Endovascular Valve Edge-to-Edge Repair Study; other abbreviations as in Table 1.
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MitraClip in Patients Not Amenable to Surgery November 15, 2011:2190–5repair (Fig. 1), while minor residual MR was left untreated
in the other patient. Clip detachments were remedied by
placing another clip during the same procedure in 1 patient
and on the next day in the other patient. One patient
experienced intraprocedural ventricular tachycardia that was
terminated by external defibrillation, and 1 patient devel-
oped transient third-degree atrioventricular conduction
block that did not necessitate pacemaker implantation. This
patient also required 2 U of blood transfusion, as did 8 other
patients. Thus, overall, periprocedural complications were
encountered in 14 patients (13.5%).
Clinical outcomes. Median follow-up duration was 359
days (interquartile range: 248 to 404 days).
PATIENTS WITH SUCCESSFUL INDEX PROCEDURES. Six of
he 96 patients with successful index procedures underwent
epeat clipping at a median of 140 days (interquartile range:
8 to 351 days), and 2 underwent MV surgery (1 repair, 1
eplacement) at 47 and 58 days (Fig. 1). Surgical repair was
lso performed in 1 patient shortly after a failed attempt at
epeat clipping.
Follow-up was obtained by telephone (n  18) or clinical
visit (n  63) in 81 surviving patients. New York Heart
Association (NYHA) functional class had improved in 65
patients (80%), with a total of 56 patients (69%) in NYHA
functional class I or II at follow-up. The 6-min walk
distance improved in 41 of 55 patients (75%), MLHFQ
score improved in 35 of 47 patients (74%), and NT-
proBNP decreased in 32 of 52 patients (62%). The overall
Figure 1 Patient Flow Chart
*No clip implanted (n  3) or residual mitral regurgitation 2. F  failure; IQR 
Questionnaire; NT-proBNP  N-terminal pro–brain natriuretic peptide; NYHA  New
6MWT  6-min walk test.changes in these variables from baseline to follow-up are Mshown in Figure 2. Baseline MR severity did not influence
any outcome measure (Online Appendix). Of note, when
counting patients who died (n  15) as deteriorations,
statistical significance was maintained for NYHA functional
class, 6-min walk distance, and MLHFQ score, but not for
NT-proBNP, in a sensitivity analysis using the sign test.
PATIENTS WITH FAILED INDEX PROCEDURES. Of 8 patients
ith failed index procedures, 1 patient underwent MV
eplacement on the same day and 1 patient had surgical MV
epair after 2 days (Fig. 1). The latter patient underwent
alve replacement 3 months later. Of 6 patients without
mmediate MV surgery, 1 patient underwent MV replace-
ent at 49 days, and 2 patients had repeat MitraClip
rocedures. Both repeat interventions were failures (no clip
n 1 patient, residual MR grade 3 in the other), and 1 was
ollowed by surgical valve repair 4 days later.
chocardiographic follow-up. Compared with baseline,
R grade at follow-up was significantly improved; no change
n left ventricular (LV) ejection fraction was observed, yet LV
nd-diastolic and end-systolic volumes decreased significantly.
V forward stroke volume increased significantly, whereas
otal stroke volume showed a significant reduction (Table 3).
ajor adverse events. Twenty-six patients (25%) died
etween 10 and 698 days after the intervention (median 162
ays); there were 4 in-hospital deaths. Deaths were adjudi-
ated as cardiac in 19 patients (18%).
Thirteen patients required reinterventions (13%). Repeat
quartile range; MC  MitraClip; MLHFQ  Minnesota Living With Heart Failure
Heart Association; S  success; TTE  transthoracic echocardiography;inter
YorkitraClip procedures were performed in 8 patients and
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November 15, 2011:2190–5 MitraClip in Patients Not Amenable to Surgeryfailed in 2. MV surgery was performed in 7 patients (3
repairs, 5 replacements, 1 patient with both) (Fig. 1).
Twenty-eight patients (27%) were rehospitalized for
cardiac decompensation. Independent predictors of cardiac
rehospitalization were a baseline LV ejection fraction45%
(odds ratio: 3.90; p 0.008) and a forward stroke volume at
discharge 50 ml (odds ratio: 4.54; p  0.007).
Overall, 57 patients (55%) experienced at least 1 major
adverse event (i.e., cardiac rehospitalization, reintervention,
Figure 2 Clinical and Laboratory Measures of Patient Outcome
Box plots showing baseline (BL) and follow-up (F/U) distributions of 6-min walk dis
and N-terminal pro–brain natriuretic peptide (NT-proBNP) levels in patients with su
Changes in Echocardiographic Variables From BTable 3 Changes in Echocardiographic Varia
Variable n
MR grade 63
1
2
3
4
Regurgitant jet/LA area ratio (%) 53
LV end-diastolic volume (ml) 63
LV end-systolic volume (ml) 63
LA volume (ml) 57
Total stroke volume (ml) 63
FSV (ml) 59
Regurgitant volume (ml) 59
Regurgitant fraction (%) 59
LV ejection fraction (%) 63
LV end-diastolic diameter (mm) 59
LV end-systolic diameter (mm) 59
Mean transmitral gradient (mm Hg) 54Values are n (%), mean  SD, or median (interquartile range).
FSV  forward stroke volume; LA  left atrial; other abbreviations as in Taor death). Kaplan-Meier estimates of freedom from death,
cardiac rehospitalization, or reintervention are shown in
Figure 3. Estimates of 1-year mortality and rehospitaliza-
tion were 22% and 31%, respectively.
Baseline MR grade 4 and discharge forward stroke
volume 50 ml independently predicted event-free survival
on multivariate analysis (Table 4).
For a comparison of patients with functional versus
degenerative MR, see the Online Appendix.
Minnesota Living With Heart Failure Questionnaire (MLHFQ) score,
ul index procedures. Numbers beside boxes are medians.
ne to Follow-UpFrom Baseline to Follow-Up
aseline Follow-Up p Value
0.0001
(0%) 14 (22%)
(2%) 38 (60%)
(56%) 10 (16%)
(43%) 1 (2%)
6 12 21 14 0.0001
(174–281) 183 (150–233) 0.0001
(87–193) 102 (73–166) 0.0002
(59–113) 87 (61–119) 0.1130
(70–108) 69 (57–89) 0.0001
(31–53) 49 (42–59) 0.0001
(35–62) 19 (12–36) 0.0001
(42–60) 28 (17–37) 0.0001
(31–52) 45 (30–53) 0.1577
5 11 66 11 0.7020
4 13 53 14 0.6634
.3 2.0 3.7 2.2 0.0001tance,
ccessfaselibles
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Our study demonstrates that in patients with severe MR not
amenable to surgery, MitraClip therapy leads to sustained
reduction in MR severity and reverses ventricular remodel-
ing. Significant clinical improvement was observed in three-
quarters of patients followed.
Figure 3 Event-Free Survival
Cumulative survival curves for freedom from death, reintervention, cardiac rehospi
freedom from death, cardiac rehospitalization, and reintervention.
Cox Regression Analyses for Death,ardiac Rehospitalization, R interventionTable 4 Cox Regres ion Analyses for Death,Cardiac Rehospitalization, or Reintervention
Variable OR 95% CI p Value
Univariate analysis
Age 0.977 0.947–1.008 0.150
EuroSCORE 1.007 0.995–1.020 0.256
Baseline LV ejection fraction 0.982 0.965–1.000 0.054
Baseline LV ejection fraction 45% 1.872 1.074–3.264 0.027
Baseline FSV 0.987 0.972–1.001 0.075
Baseline FSV 50 ml 2.593 1.352–4.972 0.004
Discharge FSV 0.987 0.975–1.000 0.052
Discharge FSV 50 ml 2.495 1.364–4.563 0.003
Change in FSV from baseline to
discharge
0.994 0.978–1.009 0.433
Change in regurgitant jet/LA area
ratio from baseline to discharge
0.997 0.977–1.018 0.791
MR etiology* 0.967 0.551–1.696 0.907
Baseline MR grade 4 1.739 1.016–2.978 0.044
Baseline NYHA functional class IV 1.661 0.980–2.813 0.059
Multivariate analysis
Baseline LV ejection fraction 45% 1.603 0.838–3.069 0.154
Baseline MR grade 4 1.823 1.003–3.314 0.049
Baseline FSV 50 ml 1.372 0.592–3.180 0.460
Discharge FSV 50 ml 2.208 1.065–4.577 0.033*Degenerative/mixed versus functional.
CI  confidence interval; OR  odds ratio; other abbreviations as in Tables 1 and 3.Patient population. Compared with EVEREST II, the
present study population differed considerably with respect
to age, comorbidities, and the prevalence of functional MR.
Moreover, 80% of our patients had valve morphologies that
met EVEREST II exclusion criteria (1). Nevertheless, an
overall procedural success rate of 92% was achieved in our
study, demonstrating the general feasibility of the procedure
in patients at prohibitive surgical risk. The higher proce-
dural success rate compared with EVEREST II may be
explained by 2 factors: 1) in the present study, 2 experienced
operators performed all interventions; and 2) functional
MR, which tends to be easier to intervene on, was more
prevalent. The rate of periprocedural complications was low,
with in-hospital mortality of 3.8%; expectedly, this is higher
than the 1.1% mortality in the EVEREST II population but
in the 2% to 10% range reported for MV surgery in
high-risk patients (4,5). Importantly, the severity of comor-
bidities exceeded not only that commonly encountered in
MV surgery studies but also that reported for patients
denied MV surgery (6). Compared with EVEREST II, our
patients exhibited higher NYHA functional classes, yet
quantitative measures of MR severity tended to be lower,
possibly because of the more advanced LV dysfunction in
our patients. Thus, not only do patients with cardiomyop-
athy have a higher degree of functional impairment, but also
the severity of mostly functional MR in these patients shows
a high degree of variation, with a tendency toward under-
estimation in recompensated patients scheduled for
intervention.
Clinical outcomes. Most of the patients followed exhib-
on, and the composite endpoint oftalizatiited significant improvements in clinical status. NYHA
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November 15, 2011:2190–5 MitraClip in Patients Not Amenable to Surgeryfunctional class was reduced, with almost 70% of patients in
class I or II. This effect was observed on top of optimal
medical therapy and in highly symptomatic patients: as
opposed to EVEREST II, with 49% of patients in NYHA
functional class I or II, we included only patients in NYHA
functional class III or IV. Also, MLHFQ score improved by
almost 20 points, which is comparable with results reported
for MV surgery (7). In accordance, 6-min walk distance
increased in 75% of our patients, further underscoring the
profound clinical benefit derived from this therapy in the
majority of patients included.
Of the 13% of patients in whom reintervention was
necessary, 6% could be retreated with the MitraClip,
whereas 7% eventually required MV surgery. This incidence
compares favorably with the 20% necessity for surgery in
EVEREST II (1), implying that patients with prohibitive
surgical risk do not exhibit higher reintervention rates.
Echocardiography. Echocardiographic baseline parame-
ters in the present study underscore the population’s overall
high morbidity. Yet, in concordance with EVEREST II (1),
LV volumes were significantly reduced at follow-up.
Major adverse events. The 55% overall event rate was
riven mainly by mortality and rehospitalization (25% and
7%, respectively). These data mirror the high morbidity of
ur cohort and are in accordance with data reported from
he EVEREST II high-risk registry, which revealed a
-year mortality of 24% after MitraClip implantation in
atients with similar risk profiles, as opposed to 45% in
atients on medical therapy only (8); these rates suggest that
itraClip implantation may indeed slow the progression of
he disease. In the present study, a forward stroke volume at
ischarge of 50 ml emerged as the most powerful predic-
or for both rehospitalization and the composite endpoint of
eath, rehospitalization, and reintervention. This observa-
ion potentially indicates that LV contractile reserve (i.e.,
he ability of the left ventricle to procure sufficient contrac-
ility for enhancement of forward stroke volume) is of
rognostic importance (9). Of note, MR etiology (i.e.,
unctional vs. degenerative) had no influence on the pa-
ients’ clinical outcomes, implying that MitraClip therapy is
qually effective for both conditions.
tudy limitations. This study was relatively small in size,
nd a considerable number of patients were lost to follow-
p. Those patients were on average older and more often in
YHA functional class IV at baseline. The lack of
ollow-up data in patients who died before assessment may
ave caused an optimistic selection bias. However, a sensi-
ivity analysis revealed that only the decrease in NT-
roBNP may be spurious.
onclusions
his study extends the current body of evidence showing
hat MitraClip therapy is safe and efficacious in patientswith significant MR deemed at prohibitive surgical risk;
it resulted in significant clinical improvements at 1 year in
about three-quarters of patients followed. The subgroup
analyses of EVEREST II suggest that older age, func-
tional MR, and reduced ejection fraction describe pa-
tients deriving particular benefit from this therapy (1).
The present study, which largely included patients with
these characteristics, reinforces this tenet and may point
toward novel treatment options not only in patients
considered at excessive surgical risk. Further research is
needed to identify parameters that will more decisively
discriminate between patients who will and those who
will not derive benefit from the procedure in the long
term.
Reprint requests and correspondence: Dr. Stephan Baldus,
Department of General and Interventional Cardiology, University
Heart Center Hamburg, 20246 Hamburg, Germany. E-mail:
baldus@uke.de.
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APPENDIX
For a summary of echocardiographic and statistical methods and
supplemental tables, please see the online version of this article.
